@article {Fernandez1367, author = {Leticia Fernandez and Gabriela Franco Salinas and Cecilia Rocha and Carla E Carvalho-Pinto and Nataliya Yeremenko and Laura Papon and Jan Paul Medema and Bernard Combe and Jacques Morel and Dominique Baeten and Michael Hahne}, title = {The TNF family member APRIL dampens collagen-induced arthritis}, volume = {72}, number = {8}, pages = {1367--1374}, year = {2013}, doi = {10.1136/annrheumdis-2012-202382}, publisher = {BMJ Publishing Group Ltd}, abstract = {Background The tumour necrosis factor (TNF)-family members B cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) play important roles in B cell biology, and share binding to B cell maturation antigen and transmembrane activator and cyclophilin ligand interactor, both receptors of the TNF-family. However, while it is reported that BAFF can break B cell tolerance, the role of APRIL in autoimmunity remains elusive. Objective To evaluate the role of APRIL on collagen-induced arthritis (CIA). Methods CIA was induced in APRIL-transgenic (Tg) DBA/1 mice and littermates. Disease progression was evaluated by clinical and histological signs of arthritis. In another experimental setting mice were exposed to the collagen antibody-induced arthritis. In addition, we tested T cell dependent humoral responses in APRIL-Tg mice. Results We found that APRIL-Tg displayed a strongly reduced incidence and severity of CIA compared with littermates, with decreases in collagen-specific autoantibody titres, immune complex deposition and downstream mast cell activation in joints. Notably, ectopic APRIL-expression was also found to negatively regulate T cell dependent humoral responses. The lower autoantibody production in APRIL-Tg mice during CIA appears to be crucial, as arthritis induced by administration of anti-collagen antibodies developed similar in APRIL-Tg and control mice, thus demonstrating that the downstream effector pathways induced by anti-collagen antibodies remain intact in APRIL-Tg mice. This protective effect was specifically mediated by APRIL, as adenoviral delivery of APRIL decreased CIA in a therapeutic setting. Conclusions Collectively, our data identify APRIL as a negative regulator of CIA by regulating autoantibody production. These findings are of important clinical relevance, as the therapeutic potential of transmembrane activator and cyclophilin ligand interactor-Fc (atacicept) is presently evaluated in clinical trials.}, issn = {0003-4967}, URL = {https://ard.bmj.com/content/72/8/1367}, eprint = {https://ard.bmj.com/content/72/8/1367.full.pdf}, journal = {Annals of the Rheumatic Diseases} }